Merck KGaA
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000BX4S53
MRK
Merck KGaA
GICS: 35202010
·
Sector: Heart drugs
·
Sub-Sector: -
NAME
Merck KGaA
ISIN
DE0006599905
TICKER
MRK
MIC
XETR
REUTERS
MRCG.DE
BLOOMBERG
MRK GR
F&G:
63
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Thu, 24.04.2025
Darmstadt, April 24, 2025 – Merck KGaA (“Merck”) reacts to press reports and confirms late-stage discussions with SpringWorks Therapeutics, Inc. on a potential acquisition. The parties are in discussion on the basis of a price of around USD 47 per share. Merck notes that no final decision has been taken and no legally binding agreement has been ent...
Mon, 10.02.2025
Darmstadt, February 10, 2025 – Merck KGaA (“Merck”) reacts to press reports and confirms advanced discussions with Springworks Therapeutics, Inc. Merck also confirms that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met.
End of insid...
Fri, 26.07.2024
Darmstadt, July 26, 2024: Based on a very strong second quarter of 2024 with net sales of EUR 5.352 bn resulting in an EBITDA pre1 of EUR 1.509 bn and an EPS pre1 of EUR 2.20, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2024. The main driver is a very strong operating performance of Healthcare and Ele...
Mon, 24.06.2024
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients ...
Mon, 24.06.2024
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients ...
Tue, 05.12.2023
Darmstadt, 5 December 2023: Merck KGaA is investigating a highly selective oral and central nervous system penetrant Bruton’s tyrosine kinase inhibitor (BTKi) as a potential treatment for relapsing multiple sclerosis ("RMS") in two pivotal phase III clinical trials (evolutionRMS 1 and evolutionRMS 2, together the "Clinical Trials"). Both Clinical T...
Wed, 03.11.2021
Darmstadt, November 3, 2021. Based on a very strong third quarter of 2021 with net sales of EUR 4.97 bn resulting in EBITDA pre1 of EUR 1.55 bn and EPS pre1 of EUR 2.24, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2021. The main driver is a very strong operating performance from the Life Science busine...
Tue, 04.05.2021
Darmstadt, 4 May 2021. Based on high demand expected to continue throughout the year and a very strong first quarter of 2021 with net sales of EUR 4.63 bn resulting in EBITDA pre1 of EUR 1.51 bn and EPS pre1 of EUR 2.18, Merck KGaA (the "Company") has raised its forecast for the entire group for fiscal 2021. The Company now projects net sales of ap...
Wed, 20.01.2021
Merck KGaA (the "Company") is investigating a bifunctional immunotherapy, bintrafusp alfa (anti-PD-L1/TGF-beta trap), as a potential therapy for difficult to treat cancers.
While reviewing the totality of data from the ongoing clinical trial INTR@PID Lung 037 in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) t...
Tue, 29.09.2020
Darmstadt, September 29, 2020. In the United States Merck KGaA's subsidiary EMD Serono, Inc. (Merck) is involved in a US patent dispute with Biogen Inc., United States (Biogen). Biogen sued Merck for damages in connection with a patent infringement caused by Merck's product Rebif before the U.S. District Court New Jersey, Newark. Merck defended its...
Information on product placements
BARRISTA SMART * AD
P R O D U C T S U G G E S T I O N S
